Literature DB >> 19887729

BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse.

Shigeyuki Ozawa1, Yasumasa Kato, Eiro Kubota, Ryu-Ichiro Hata.   

Abstract

SCID mice are a model of human severe combined immunodeficiency disease and are deficient in B cell function in addition to T cell function. Tumors from other species are easily transplanted into SCID mice and will grow without being rejected. We previously reported that the chemokine BRAK/CXCL14 is expressed in normal cells but its expression is down regulated in an in vitro cancer progression model, suggesting that it has the potential for antitumor activity. Here we report that the growth of BRAK/CXCL14 expression vector-transfected oral cancer cells was completely (100%) suppressed in SCID mouse xenografts even though mock-vector introduced control tumor cells grew well with 100% of animals developing tumors. In addition, suppression of xenografts was much faster and the rate was much higher in SCID mice than in T cell function-deficient nude mice. These data indicate the possibility that BRAK expression inhibits tumor cell establishment by regulating interactions between tumor stem cells and NK cells and/or suppressing formation of tumor microvessels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887729     DOI: 10.2220/biomedres.30.315

Source DB:  PubMed          Journal:  Biomed Res        ISSN: 0388-6107            Impact factor:   1.203


  12 in total

1.  Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected]

Authors:  Kazuhito Izukuri; Kenji Suzuki; Nobuyuki Yajima; Shigeyuki Ozawa; Shin Ito; Eiro Kubota; Ryu-Ichiro Hata
Journal:  Transgenic Res       Date:  2010-03-24       Impact factor: 2.788

2.  A striking local esophageal cytokine expression profile in eosinophilic esophagitis.

Authors:  Carine Blanchard; Emily M Stucke; Beatriz Rodriguez-Jimenez; Karen Burwinkel; Margaret H Collins; Annette Ahrens; Eileen S Alexander; Bridget K Buckmeier Butz; Sean C Jameson; Ajay Kaul; James P Franciosi; Jonathan P Kushner; Philip E Putnam; J Pablo Abonia; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2011-01       Impact factor: 10.793

Review 3.  The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.

Authors:  Joseph A Westrich; Daniel W Vermeer; Paul L Colbert; William C Spanos; Dohun Pyeon
Journal:  Mol Carcinog       Date:  2020-03-24       Impact factor: 4.784

4.  Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection.

Authors:  Jun Zeng; Xudan Yang; Lin Cheng; Rui Liu; Yunlong Lei; Dandan Dong; Fanghua Li; Quek Choon Lau; Longfei Deng; Edouard C Nice; Ke Xie; Canhua Huang
Journal:  J Transl Med       Date:  2013-01-07       Impact factor: 5.531

5.  Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.

Authors:  Angela Pennisi; Wen Ling; Xin Li; Sharmin Khan; Yuping Wang; Bart Barlogie; John D Shaughnessy; Shmuel Yaccoby
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

Review 6.  Chemokine function in periodontal disease and oral cavity cancer.

Authors:  Sinem Esra Sahingur; W Andrew Yeudall
Journal:  Front Immunol       Date:  2015-05-05       Impact factor: 7.561

7.  Transcriptional and Linkage Analyses Identify Loci that Mediate the Differential Macrophage Response to Inflammatory Stimuli and Infection.

Authors:  Musa A Hassan; Kirk D Jensen; Vincent Butty; Kenneth Hu; Erwan Boedec; Pjotr Prins; Jeroen P J Saeij
Journal:  PLoS Genet       Date:  2015-10-28       Impact factor: 5.917

8.  A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma.

Authors:  Ryu-Ichiro Hata
Journal:  ISRN Otolaryngol       Date:  2012-11-14

9.  Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice.

Authors:  Ryu-Ichiro Hata; Kazuhito Izukuri; Yasumasa Kato; Soichiro Sasaki; Naofumi Mukaida; Yojiro Maehata; Chihiro Miyamoto; Tetsu Akasaka; Xiaoyan Yang; Yoji Nagashima; Kazuyoshi Takeda; Tohru Kiyono; Masaru Taniguchi
Journal:  Sci Rep       Date:  2015-03-13       Impact factor: 4.379

Review 10.  Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment.

Authors:  Martin Augsten
Journal:  Front Oncol       Date:  2014-03-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.